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Abstract
Previous research suggests that the efficacy of Ertapenem, a carbapenem antibiotic
administered intravenously, is related to a patient’s body mass index. Using an existing
physiologically based pharmacokinetic (PBPK) model for Ertapenem, we constructed a
least squares inverse problem to determine an optimal dose for males with varying body
weights and heights. The criteria for an optimal dose was based upon pharmacokinetic
and pharmacodynamic (PK/PD) parameters calculated for a male with a body height
of 175 cm and a weight of 72 kg. We also adjusted dosing intervals to ensure that
effective concentration of drug between doses was the same for all males regardless of
BMI.
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1 Introduction
Antibiotic resistance continues to be a major public health concern. A patient may become
infected by antibiotic resistant bacteria in two ways: by being exposed to a strain of bacteria
that is already resistant (usually in a hospital setting) or by receiving ineffective treatment.
It is estimated that there are at least 2 million cases of antibiotic resistant infections that
cause at least 23,000 deaths in the United States each year [5].
One measure to prevent the development of resistant strains is by giving patients a
dose that sufficiently inhibits bacterial growth. If the bacteria causing the infection are
able to multiply, then they have the potential to produce mutants that either require a
higher concentration of antibiotic to be killed or are completely resistant to that antibiotic
at any concentration [16, 24]. Thus, it is crucial that a patient receives a large enough dose
such that these mutations can be prevented.
However, as the dose of an antibiotic increases, so does the possibility of a patient
experiencing adverse effects [2, 23]. For example, higher doses are more likely to kill
the micro flora in a patient’s bowels making them susceptible to C. difficile-associated
disease (CDAD)[23]. Moreover, at high enough concentrations, antibiotics can become
toxic, causing organ failure or lowering an individual’s seizure threshold [2, 3, 27].
The effective concentration of an antibiotic in a person is not only dependent on the dose
they receive, but also certain physiological features which can impact the kinematics of the
drug. In particular, body weight, BMI, age, and gender have all been shown to sometimes
be relevant factors [18, 19]. Nevertheless, investigating this potential variability is not
always feasible without sufficient evidence as performing clinical trials on a large enough
population is both expensive and time-consuming. Fortunately, mathematical modeling
based on well-established pharmacological principles can provide insight on how a particular
dose might impact different demographics without putting any subjects at risk. This
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strategy can also be used to make suggestions on what dose might be appropriate for a
certain class of individuals.
1.1 Pharmacokinetics and Pharmacodynamics
Pharmacology is divided into two primary branches: pharmacokinetics and pharmacody-
namics. Pharmacokinetics (PK) is the study of how a drug travels through the body;
whereas, pharmacodynamics (PD) is the study of how a drug interacts with the body [25].
When determining antibiotic doses, it should be noted that only the free concentration of
the drug is considered to be medicinally effective [6, 23]. The free concentration of a drug
is defined as the portion of the drug in the blood that is not bound to plasma proteins [25].
Using PK concepts, one can determine how the amount of free concentration in the blood
changes after the initial dose. This information defines a curve modeling free concentration
over time (for an example, see Figure 2 in Section 2). The characteristics of this curve are
considered to be related to PD concepts – positive or adverse affects, and antimicrobial
activity [6].
In particular, there are 2 main attributes of these curves that indicate an antibiotic’s
efficacy: the peak free concentration (CBfmax) and the area underneath the free concen-
tration curve (AUC). Both of these values are dependent on the rate of absorption and
considered to be indicators of toxicity [23, 25]. These values, along with the minimum in-
hibitory concentration (MIC) for a particular bacteria, all serve as components of the three
primary PK/PD parameters considered to determine whether an antibiotic will be effective
against a particular bacteria [6, 23, 25]. Which PK/PD parameter to use is determined by
the assumed mechanism of action of an antibiotic [6].
For certain antibiotics, like Aminoglycosides and Flouroquinolones, the concentration
of the antibiotic directly correlates with bacteria eradication [23, 25]. These antibiotics are
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referred to as concentration-dependent and their key parameter is the ratio of the peak
free concentration and the MIC value of the bacteria of interest (CBfmax/MIC) [6, 15, 23].
Antibiotics are classified as time-dependent if bacterial eradication does not increase with
higher concentrations above the MIC. Instead, the efficacy of these antibiotics is dependent
on the length of time that the concentration is above the MIC (ex. β-lactams). Because
of this, the key metric for time-dependent antibiotics is the percentage of time above the
MIC. (%T > MIC)[6, 15, 23]. Some antibiotics are considered to be both concentration-
dependent and time-dependent – both the concentration and the length of time the are
good predictors of efficacy [6, 15, 23]. To account for both of these dependencies, the
parameter for these antibiotics (ex.Vancomycin) is the area underneath the curve over the
minimum inhibitory concentration (AUC/MIC) [6, 15, 23]. Notably, once the parameter
value for a specific bacteria and antibiotic is achieved, the antibiotic is not considered to
be more effective at higher doses [6, 23].
1.2 Ertapenem
Effective against both gram-positive and gram-negative bacteria, Ertapenem is approved
by the FDA to treat complicated intrabdominal infections, skin and structure infections,
and urinary tract infections, as well as community acquired pneumonia, and uncompli-
cated pelvic infections [7]. The current dosing guidelines state that adults without renal
impairment should be given a 1 gram dose intravenously for 3-14 days depending on the
infection [10].
The efficacy of a dose of Ertapenem, like other β-lactams, is considered to be time-
dependent. Ertapenem is considered to be effective at eradicating a particular bacteria
when the free concentration is above the bacteria’s MIC value for 40% of the dosing interval
[15]. The kinematics of Ertapenem, modeled by Joyner et. al and described further in the
7
subsequent section, suggests that a good portion of the drug is stored in the fat affecting
the amount of free concentration available to stop the infection [11, 12] .
This is of particular importance as Ertapenem is a broad spectrum antibiotic so its
misuse has the potential to cause the development of multi-drug resistant bacteria [14]. In a
retrospective study of the use of Ertapenem in a Singapore Hospital from 2006-2008, it was
found that although Ertapenem was administered according to the current guidelines, there
were still reported incidents of patients who had been treated with Ertapenem developing
carbapenem resistant bacteria. The recommendations of this study was for doctors to
continue to prescribe Ertapenem judiciously and to administer an adequate dose [17].
1.3 Mathematical Model
The kinetics of Ertapenem have been modeled by Joyner et. al using a physiologically based
pharmacokinetic (PBPK) model [12]. A PBPK model divides the body into compartments
and models the changing concentration of a drug in each compartment by system of differ-
ential equations. More specifically, these models utilize the volume of each compartment
and their respective flow rates by accounting for physiological traits like weight, height,
and gender [25]. These models can be useful in identifying a physiological factor that might
impact the efficacy of a drug in a class of individuals. Joyner et. al’s full model for males
is defined in equation (5) and is described below. [12]. The mathematical model includes
a compartment for the blood (Bl), the kidneys (K), the fat (F ), the gut (G), and other
tissues (OT ). The model also accounts for the amount of the drug excreted in the urine
(u) and the feces (f) separately.
The volumes of the compartments used in the model, with exception of VOT ,were
calculated using the following equations found in the literature [20, 22] :
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VBl =
13.1(BH)(100) + 18.05(BW ) − 480
0.5723
VK = 15.4 + 2.04(BW ) + 51.8(BH)
2
VF =
%BF
100 (BW )
0.923
VG = 0.0171(BW )(1000)
VOT = 1000(BW ) − (VBl + VF + VK + VG)
(1)
To account for the differences in BMI, sex (0 for males; 1 for females), and age, the per-
cent Body Fat (%BF ) used to determine the volume of the fat compartment was calculated
using the following equation [8]:
%BF = −96.07 + (76.91 log10(BMI)) + (6.65 log10(Age)) + (11.40Sex) (2)
Notably, the model accounts for both the concentration of Ertapenem that is bounded in
the albumin and is unbounded [11, 13, 21]. This relationship is described in the following
equations:
CBl = CBf + CBound (3)
CBf =
CBl −Bm −Kd +
√
(Bm +Kd − CBl)2 + 4KdCBl
2
(4)
The full model is included below and a summary of the variables is included in Figure 1:
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VF
dCF
dt
= QF
(
αCBf −
CF
PF
)
VK
dCK
dt
= QK
(
αCBf −
CK
PK
− kuCK
)
VG
dCG
dt
= QG
(
αCBf −
CG
PG
− kfCG
)
VOT
dCOT
dt
= QOT
(
αCBf −
COT
POT
)
VBl
dCBl
dt
= QF
CF
PF
+QK
CK
PK
+QG
CG
PG
+QOT
COT
POT
− αQTotalCBf +RI
dAu
dt
= kuCK
dAf
dt
= kfCK
(5)
with the rate of infusion being defined as
RI =

D
TI
, 0 ≤ t ≤ TI
1, t > TI
(6)
and the body’s total flow rate is calculated by body weight using the following equation
[26]:
QTotal = 235(BW )
0.71(60). (7)
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Figure 1: Summary of variables from Joyner et. al [12]
1.4 Impact of BMI and Gender
The mathematical model described in the previous section was used to investigate the im-
pact of Body Mass Index (BMI) and gender on the efficacy of Ertapenem. When simulating
this model for various BMIs, it was found that BMI did directly impact the profile of the
concentration curve. Notably, those with a higher BMI had a smaller AUC and a lower
maximum free concentration compared with those with an optimal BMI. Conversely, those
with lower BMI had a larger free AUC and a higher peak free concentration. These results
suggest that those with a lower BMI might be at risk for developing adverse reactions to
Ertapenem and those with a higher BMI might be at risk for not having enough concen-
tration to be appropriately effective [12]. They also found that gender had an impact as
well. It was found that the free concentrations for females spanned a larger range of values
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than for males. It was also found that BMI impacted the half-life of the drug for males,
but less so females [12].
1.5 Present Work
The current paper is motivated by the previous work done by Joyner et al. [12]. The
objective of this research is to determine if an optimal dose can be determined for different
classes of BMI for males. For the purposes of this paper, we define an optimal dose to be
one that maximizes bacterial inhibition while minimizing the chances of toxicity or adverse
side effects. Because of this, we focus on optimizing the peak free concentration (CBfmax),
the area under the concentration curve (AUC), and the time that the concentration is
above the minimum inhibitory concentration (MIC).
2 Determining optimal PK/PD parameters
Since the concentration values for a male receiving a 1g/day dose with the body height of
175 cm and body weight of 72 kg (hereafter referred to as the typical male) provided in
the pamphlet distributed by Merck & co., received FDA approval, we assume that those
values are optimal [10]. Moreover, since these values were used by Joyner et. al to fit
their PBPK model, we assume that the attributes of the model’s concentration curves for
a male with the body height of 175 cm and body weight of 72 kg are also optimal [12]. We
first simulated the PBPK model for one 1 gram dose for the typical male using Matlab.
Because we were only interested in determining an optimal dose based upon BMI, we kept
age constant at 39 years. We also assumed there was no Ertapenem in the system initially
so we set all of our initial conditions of our model to be zero.
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Figure 2: This figure is the free concentration in the blood across time for a typical male
from 0-12 hours. The AUC is the area shaded in light blue, CBf,max is the max concen-
tration value, and MICmax is depicted with a red-dotted line.
Figure 2 shows the quantities of interest for this study. CBfmax is shown as the peak
concentration, occurring after the initial infusion time. To determine this value, we used the
Matlab function max and found for the typical male, the value is approximately 15.3mcgmL
[MATLAB:2017b]. The area under the concentration curve AUC is shown in Figure
2’s shaded blue region. In order to calculate this, we needed to integrate CBf across
the dosing interval (0 to 24 hours). We estimated the integral by using the Matlab
function trapz which numerically approximates this integral using the trapezoidal rule
[MATLAB:2017b]. The trapezoidal rule calculates an estimate for area by first splitting
the independent variable into partitions and evaluating the function at these partitions.
These values are then used to construct trapezoids so that when the areas of all of these
trapezoids are added together they produce an estimate for the overall area underneath
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the curve [9]. We found that for typical male the AUC0−24 to be 2.8 × 104mcgmL .
Instead of optimizing dose for a particular bacteria, we decided to use the largest pos-
sible MIC value that 1 g dose for a typical male would be effective against. We denote this
value as MICmax and is represented in Figure 2 with a red dashed line. To calculate this,
we leverage the fact that Ertapenem is considered to be effective against a particular bac-
teria when the free concentration in the blood is above the bacteria’s minimum inhibitory
concentration for more than 40% of the dosing interval [15].
In an effort to be conservative, we defined MICmax to be the maximum value that
the free concentration is greater than or equal to for 41% of the dosing interval. To
calculate this value, we simulated the model for a typical male and found the minimum
free concentration in the 59th percentile. This method to find MICmax satisfies the above
definition as the simulated free concentration values in the 59th percentile correspond to
the highest free concentration for 41% of the time interval.
Thus, we consider the free concentration of 0.6872 (g)(mL) to be our optimal value for
MICmax. Note, for the typical male this value is the same after each additional dose as
well. This is because in the model for a typical male there is not any Ertapenem leftover
in the system for a 1 g dose after 24 hours. We summarize the values of interest for the
optimization problem in Table 1.
Table 1: Rounded Parameter values used in cost function, J(D;BW,BH), to optimize
dosage.
Parameter Model value Units
CBfmax 15.3
(mcg)
(mL)
AUC0−24 2.8e+ 04
(mcg)
(mL) t
MICmax 0.6872
(mcg)
(mL)
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3 Optimizing dose
3.1 Inverse Problem
To determine an optimal dose, we constructed a least squares inverse problem using the
calculated values of CBfmax , AUCBf , and MICmax from the typical male as our true
data against which we would like to optimize. More specifically, we are assuming that
the optimal dose D will on an individual’s body weight (BW ) and body height (BH);
therefore, we constructed the cost function, J(D;BW,BH) in Equation (8), to compare
these optimal values with the model outputs for different dosages D for a given body
weight (BW ) and body height (BH). Since the values of CBfmax , AUCBf , and MICmax
are all different orders of magnitude, we built our cost function to compare the relative
error between the optimal values and the model output, i.e. a weighted cost function with
the weights as the given data as follows:
J(D;BW,BH) =
(
CBfmax − CBfmax,pred(D;BW,BH)
)2
CBfmax
+
(AUCBf −AUCBf,pred(D;BW,BH))2
AUCBf
+
(MICmax −MICmax,pred(D;BW,BH))2
MICmax
(8)
Note, when a dose, D, produces a small value for J , this indicates that this dose
produces a CBfmax , AUCBf , and MICmax that are close to the values for the typical
male. To calculate the dose that produces the smallest possible J and thus minimizes the
relative error the most, we used the built in Matlab function fminsearch. This function
utilizes a Nelder-Mead algorithm which is an iterative procedure that estimates parameters
based upon an initial guess. The algorithm works by using estimated parameter values
and evaluating the cost or error that these values produce. If an estimated parameter
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value produces a lower error than the previous estimate, the algorithm will make its next
estimate in the same direction, otherwise the algorithm will pivot and estimate a parameter
in another direction. This process is continued until the difference in the error values
converge to a certain threshold. For our investigation, we chose an initial guess for D to
by 1g and used a threshold of 10−6 [1].
Note in the above procedure that D is the only parameter being varied. Thus, to obtain
an optimal dose based on BMI, we repeated the steps above 196 times using 14 different
body heights ranging from 160 to 193 cm and 14 different body weights ranging from 56.7
to 115.7 kg. BMI was calculated after the optimization using its formal definition [4]:
BMI =
BW
BH2
. (9)
The range of values used were chosen such that they spanned BMIs considered to be
underweight to severely obese. The criteria for these classifications is recorded in Table 2
and the BMIs (rounded) considered in the study are shown in Figure 3 and our shaded
according to their classification.
Table 2: BMI with Classification [4]
Classification BMI
Underweight <18.5
Healthy 18.5-25
Overweight 25.1-30
Obese 30.1-40
Severely Obese 40.1-50
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Figure 3: BMI chart of height-weight combinations considered in optimization. BMIs are
rounded to the nearest whole number and shaded according to the classification recorded
in Table 2.
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3.2 Results
Using our cost function J(D;BW,BH), we calculated an optimal dose for each height
weight combination. The results of this optimization are depicted in Figure 4. While there
is a positive relationship between BMI and the optimized dose, this relationship is not as
clear as the relationship between body weight and the optimized dose. The results of the
optimization indicate that the relationship between a male’s body weight and optimized
dose is approximately linear. Thus, although BMI does appear to be a significant factor in
predicting optimal dose, our results suggests that dosing according to body weight should
be sufficient.
Figure 4: Optimal dose values obtained from J(D;BW ;BH) for varying BMI (right) and
for varying Body weight (left)
To evaluate the effectiveness of our optimization on maximizing the efficacy of Er-
tapenem, we simulated the model with each height weight combination with their respective
optimal dose and calculated their CBfmax and AUC values (Figure 5 & 6).
18
Figure 5: Maximum free concentration grouped by BMI and body weight. The red dashed
line represents the maximum free concentration of a typical male after a 1 g dose. On
the left, are the maximum free concentrations with the normal 1 gram dose. On the right
are the maximum free concentration values obtained from simulating the model with the
optimized dose.
As expected, when we simulate our model with the optimized doses, there is less varia-
tion in the maximum free concentration (CBfmax) than when using a 1g dose for everyone
(Figure 5). Moreover, the simulated values of CBfmax are closer to the CBfmax of the typical
male when grouped by BMI or body weight. Instead of a spread in the peak concentration
from approximately 8 mcgmL to 22
mcg
mL (a spread of 14
mcg
mL ), the range has been reduced to a
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spread from approximately 12-18 mcgmL (a spread of only 8
mcg
mL ). Similarly, the AUC values
calculated using the optimal dosages are much closer to the AUC values for a typical male
(Figure 6). In this case, we were able to reduce the spread to almost a negligible difference
when compared to the typical male.
Figure 6: Area underneath the concentration curve grouped by BMI and body weight. The
red dashed line represents the AUC of a typical male after a 1 g dose. On the left, are
the AUC values with the normal 1 gram dose. On the right are the AUC values obtained
from simulating the model with the optimized dose.
We were also interested in the impact that using the optimal dose had on the MICmax.
Using our optimal dosages, we had a greater number of height-weight combinations with
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MICmax values at or above the value of the typical male (Figure 6). However, we still
had that some of our simulations had MICmax values below the value for the typical male
(Figure 6). Recall, that if a value falls below, there is a higher probability of an individual
developing resistant bacteria.
Figure 7: Maximum MIC value for 196 body height weight simulations grouped by BMI
and body weight. On the left are the model outputs using the normal 1 g dose. On the
right are the model outputs using the optimal doses. The red dashed line indicates the
MICmax for the typical male.
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4 Adjusting dosing intervals
4.1 Methods
When using the new dosage obtained from minimizing our cost function, the differences be-
tween the typical male and the model outputs for the different height-weight combinations
of the peak free concentrations and area underneath the concentration curves decreased
significantly (Figure 5 & 6). However, there was still some variation between the maximum
MIC values (Figure 7). To mitigate this, we adjusted the length of the dosing intervals
such that the free concentration was the typical male’s MICmax value for 41% of the time.
To find this length of time for each height and weight combination, we first simulated the
model using the optimal dose and then determined the the amount of time the free con-
centration was above the MICmax value for the typical male. We then divided this time
by 0.41 to get the length of our dosing interval.
4.2 Results
The adjusted length of dosing intervals are shown in Figure 8. Interestingly, based upon
Figure 8, it appears that BMI is a better indicator of how much the dosing interval might
need to adjusted more so than body weight. For instance, examining Figure 8, we see that
given a BMI of kg/m2, the patient should be given Ertapenem every 22.5 hours instead of
24 hours. We note that the adjusted dosing interval did not vary greatly from the typical
24 hour dosing period; however, even this small change makes a change in the overall
effectiveness of the antibiotic as discussed below.
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Figure 8: Length of dosing interval by BMI (left) and body weight (right). The red dashed
line represents the dosing interval for the typical male.
Similar to our evaluation of the optimal doses, we considered the impact that these
adjusted doing times would have on the CBfmax and the AUCBf . Since the time of the
next dose dose not impact the first peak free concentration, CBfmax1 , we examined the
peak free concentration on day 7, denoted CBfmax7 , as this concentration would increase if
there were concentrations of Ertapenem leftover in the model after each day. To do this,
we simulated one day of the model assuming that there was no Ertapenem initially in the
system for a fixed height and weight. We then used the concentration values from the
previous day as our initial conditions for the next day. We repeated this process for 7 days
for all 196 combinations.
We then found the peak free concentration over those 7 days (CBfmax7) shown in Figure
9. Interestingly, although the change in the dosing time for a BMI between 15 and 30 is
only approximately a half hour, this adjustment seems to keep the CBfmax7 much closer to
the CBfmax value of a typical male.
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Figure 9: Maximum free concentration over 7 days. Top: maximum free concentration
over a span of 7 days when doses are administered ever 24 hours. Bottom: maximum free
concentration when doses are administered according to the adjusted dosing interval.
For examining the impact on the AUCBf , we calculated the AUCBf over the time of
the initial dose, TI1 , until the time immediately before the next dose, TI2 . Figure 9 shows
that the area underneath the free concentration curve over the the first adjusted dosing
interval (TI1−TI2) does decrease slightly for a male with a BMI ≥ 30 (Figure 8). Although
the AUC values from the adjusted dose vary more from the AUC of the typical male, these
values are still more in line with the typical male assuming the standard dose of 1g every
24
24 hours. (Figure 6).
Figure 10: Area under the concentration curves over the adjusted dosing interval for varying
BMIs (Left) and for varying body weights (Right). The red dashed line represents the AUC
of the typical male with a 1 g dose over 24 hours.
5 Conclusions
Creating dosing strategies for an antibiotic is a balancing act. Enough must be admin-
istered to ensure that the antibiotic will be able to effectively stop the infection without
administering an amount that could be harmful to a patient. In this project, we optimized
dose for males of varying heights and weights by comparing attributes of their free concen-
tration profiles to those of a male with a body height of 175 cm and a weight of 72 kg. We
also adjusted the dosing interval so that the MIC that the antibiotic is considered effective
against is similar despite differences in height and weight.
Based on our results, we would recommend that the amount of Ertapenem prescribed
to a patient should be based upon the their body weight and the time between doses
should be based upon their BMI. This dosing strategy appears to minimize the variation
in the CBfmax and the AUC between the typical male and other males of varying body
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weights and heights. This minimization could potentially prevent adverse reactions as
both CBfmax and the AUC can be used as indicators of toxicity. Moreover, this strategy
focuses on optimizing the maximum MIC of the antibiotic to closely match the MICmax
of a typical male to ensure that bacterial inhibition would be similar across BMIs.
Although this paper focused on optimizing dose towards the maximum MIC value that
a typical male is considered to be effective against, the methodology in this paper could be
modified to optimize dose towards the MIC of a particular bacteria. More specifically, the
dosing interval could be adjusted (as described in section 4.1) so that the free concentration
remained above the MIC of interest for over 40% of the time for each body weight and
height. The PBPK model used by Joyner et. al could then be simulated for these intervals
to check that the concentrations of the antibiotic do not exceed a certain threshold.
That being said, there are still improvements that could be made to the proposed
dosing recommendations. For example, previous research suggests that the kinematics of
Ertapenem in females differs from that of males. To provide an exhaustive dosing recom-
mendation, a similar methodology to the one recorded in this paper should be conducted
for females. Further improvements could potentially be made by investigating optimizing
the dose to account for age as well. Since proper dosing is one way to mitigate the threat
of antibiotic resistant bacteria, we hope that this research might be used as motivation to
further examine how Ertapenem is administered for different individuals.
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